Curated News
By: NewsRamp Editorial Staff
January 06, 2026
Sigyn's CardioDialysis™ Targets Heart Disease with Breakthrough Blood Purification Tech
TLDR
- Sigyn Therapeutics' CardioDialysis offers a strategic advantage by leveraging existing global dialysis infrastructure to treat cardiovascular disease more effectively than current drug therapies.
- CardioDialysis works by purifying blood to remove multiple cardiovascular disease targets, including inflammatory factors and cholesterol, using dialysis machines already available in clinics worldwide.
- This technology could significantly extend and improve the lives of millions of ESRD patients who currently have limited treatment options for cardiovascular disease.
- CardioDialysis could potentially reduce cardiovascular events by 75-95% compared to statins' 25% reduction, using existing dialysis machines in over 50,000 clinics globally.
Impact - Why it Matters
This development matters because cardiovascular disease remains the world's leading cause of death, and current drug therapies have significant limitations—particularly for vulnerable populations like end-stage renal disease patients who face 67% mortality from heart conditions. CardioDialysis™ represents a potential paradigm shift by addressing multiple disease factors simultaneously through existing dialysis infrastructure, offering hope where drugs have failed. For the millions of patients undergoing regular dialysis worldwide, this could mean extended survival and improved quality of life. More broadly, successful implementation could transform cardiovascular treatment approaches globally, potentially reducing major adverse events by 75-95% compared to statins' 25% average reduction, while creating substantial economic value through extended patient lifespans and reduced healthcare burdens.
Summary
Sigyn Therapeutics, a medical technology company developing innovative dialysis-like therapies, has released a significant note from its inventor and CEO Jim Joyce that positions its CardioDialysis™ device as a potential breakthrough in treating cardiovascular disease. The note highlights how CardioDialysis™ addresses the limitations of current treatments by targeting a broad spectrum of inflammatory factors and cholesterol-transporting lipoproteins that fuel cardiovascular progression, contrasting sharply with single-target drug therapies like statins that achieve only modest 25% reductions in major adverse cardiovascular events (MACE). By leveraging existing global dialysis infrastructure—with approximately 50,000 clinics worldwide compared to fewer than 800 specialized apheresis centers—CardioDialysis™ offers unprecedented accessibility and scalability for a therapy that could reduce MACE by 75-95%, according to American Heart Association data on similar blood purification approaches.
The company's strategic focus on end-stage renal disease (ESRD) patients represents both a critical unmet medical need and a substantial market opportunity. With cardiovascular disease accounting for approximately 67% of deaths among the four million ESRD patients worldwide who receive 640 million dialysis treatments annually, and with drug therapies proving ineffective for this population, CardioDialysis™ could be administered during regular dialysis sessions to combat disease progression. This approach not only addresses a dire health crisis but also presents significant economic implications—extending the lives of U.S. dialysis patients by just one month could boost industry revenues by approximately $2.8 billion, while the global market for similar therapies is projected to grow from $300 million in 2024 to $650 million by 2033.
Beyond its immediate application for ESRD patients, Sigyn Therapeutics' broader vision includes developing CardioDialysis™ as a first-in-industry medical device to treat cardiovascular disease globally, alongside other pipeline candidates like ImmunePrep™ for cancer immunotherapy optimization and ChemoPrep™ for enhanced chemotherapy delivery. The company's comprehensive approach to blood purification therapies, detailed further on their website at www.SigynTherapeutics.com, represents a paradigm shift in how we address complex diseases that involve multiple circulating factors. This development comes at a crucial time when cardiovascular disease remains the leading cause of death worldwide, and innovative solutions are desperately needed to overcome the limitations of conventional pharmaceutical approaches.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Sigyn's CardioDialysis™ Targets Heart Disease with Breakthrough Blood Purification Tech
